HIF-1 as a target for drug development

Nature Reviews Drug Discovery

Volumn 2, Issue 10, 2003, Pages 803-811

  Giaccia, Amato ^a   Siim, Bronwyn G ^b   Johnson, Randall S ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 1 METHYLPROPYL 2 IMIDAZOLYL DISULPHIDE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 METHOXYOXYESTRADIOL; 2 MORPHOLINO 8 PHENYLCHROMONE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; ESTRADIOL DERIVATIVE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PX 12; QUINOCARMYCIN CITRATE; TEMSIROLIMUS; THIOREDOXIN; THIOREDOXIN REDUCTASE; TOPOTECAN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VINBLASTINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CLINICAL TRIAL; COPING BEHAVIOR; DRUG DESIGN; DRUG TARGETING; HEART DISEASE; HUMAN; HYPOXIA; NONHUMAN; OXYGEN TENSION; OXYGEN TISSUE LEVEL; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; STRESS; STROKE; TUMOR VASCULARIZATION;

EID: 0242331755     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1199     Document Type: Review

References (116)

1. Semenza, G. L., Roth, P. H., Fang, H.-M. & Wang, G. L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 269, 23757-23767 (1994).
2. Goldberg, M. A., Glass, G. A., Cunningham, J. M. & Bunn, H. F. The regulated expression of erythropoietin by two human hepatoma cell lines. Proc. Natl Acad. Sci. USA 84, 7972-7976 (1987).
3. Goldberg, M. A., Dunning, S. P. & Bunn, H. F. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 242, 1412-1415 (1988).
4. Shweiki, D., Itin, A., Soffer, D. & Keshet, F. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845 (1992).
5. Graham, C. H., Forsdike, J., Fitzgerald, C. J. & Macdonald-Goodfellow, S. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int. J. Cancer 80, 617-623 (1999).
6. Bodi, I., Bishopric, N. H., Discher, D. J., Wu, X. & Webster, K. A. Cell-specificity and signaling pathway of endothelin-1 gene regulation by hypoxia. Cardiovas. Res. 30, 975-984 (1995).
7. Semenza, G. L., Koury, S. T., Nejfelt M. K., Gearhart, J. D. & Antonarakis, S. E. Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice. Proc. Natl Acad. Sci. USA 88, 8725-8729 (1991).
8. Imagawa, S., Goldberg, M. A., Doweiko, J. & Bunn, H. F. Regulatory elements of the erythropoietin gene. Blood 77, 278-285 (1991).
9. Wang, G. L. & Semenza, G. L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270, 1230-1237(1995).
10. Jiang, B. H., Rue, E., Wang, G. L., Roe, R. & Semenza, G. L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 271, 17771-17778(1996).
11. Wenger, R. H.. Kvietikova, I., Rolfs, A., Gassmann, M. & Marti, H. H. Hypoxia-inducible factor-1α is regulated at the post-mRNA level. Kidney Int. 51, 560-563 (1997).
12. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl Acad. Sci. USA 95, 7987-7992 (1998).
13. Pugh, C. W., O'Rourke, J. F., Nagao, M., Gleadle, J. M. & Ratcliffe, P. J. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the α subunit. J. Biol. Chem. 272, 11205-11214 (1997).
14. Srinivas, V., Zhang, L. P., Zhu, X. H. & Caro, J. Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor α (HIF-α) proteins. Biochem. Biophys. Res. Commun. 260, 557-561 (1999).
15. Jiang, B. H., Zheng, J. Z.. Leung, S. W., Roe, R. & Semenza, G. L. Transactivation and inhibitory domains of hypoxia-inducible factor 1α. Modulation of transcriptional activity by oxygen tension. J. Biol. Chem. 272, 19253-19260 (1997).
16. Ema, M., Taya, S., Yokotani, N., Sogawa, K., Matsuda, Y. & Fujii-Kuriyama, Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl Acad. Sci. USA 94, 4273-4278 (1997).
17. Flamme, I., Frolich, T. & Risau, W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J. Cell. Physiol. 173, 206-210 (1997).
18. Hogenesch, J. B. et al. Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. J. Biol. Chem. 272, 8581-8593 (1997).
19. Tian, H., McKnight, S. L. & Russell, D. W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11, 72-82 (1997).
20. Gu, Y. Z., Moran, S. M., Hogenesch, J. B., Wartman, L. & Bradfield, C. A. Molecular characterization and chromosomal localization of a third α-class hypoxia inducible factor subunit, HIF3α. Gene Expr. 7, 205-213 (1998).
21. Salceda, S. & Caro, J. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions, Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 272, 22642-22647 (1997).
22. Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275 (1999).
23. Ohh M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Linden protein. Nature Cell Biol. 2, 423-427 (2000).
24. Gassmann, M., Chilov, D. & Wenger, R. H. Regulation of the hypoxia-inducible factor 1α. ARNT is not necessary for hypoxic induction of HIF-1α in the nucleus. Adv. Exp. Med. Biol. 475, 87-99 (2000).
25. Kamura, T. et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284, 657-661 (1999).
26. Kibel, A., Iliopoulos, O., DeCaprio, J. A. & Kaelin, W. G. Jr. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269, 1444-1446 (1995).
27. Lonergan, K. M. et al. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol. Cell. Biol. 18, 732-741 (1998).
28. Pause, A. et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins, Proc. Natl Acad. Sci. USA 94, 2156-2161 (1997).
29. Pause, A., Peterson, B., Schaffar, G., Stearman, R. & Klausner, R. D. Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein. Proc. Natl Acad. Sci. USA 96, 9533-9538 (1999).
30. Deshaies, R. J. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu. Rev. Cell Dev. Biol. 15, 435-467 (1999).
31. Koepp, D. M., Harper, J. W. & Elledge, S. J. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 97, 431-434 (1999).
32. Tyers, M. & Jorgensen, P. Proteolysis and the cell cycle: with this RING I do thee destroy. Curr. Opin. Genet. Dev. 10, 54-64 (2000).
33. Duan, D. R. et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269, 1402-1406 (1995).
34. Tanimoto, K., Makino, Y., Pereira, T. & Poellinger, L. Mechanism of regulation of the HIF-1α by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19, 4298-4309 (2000).
35. Cockman, M. E. et al. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275, 25733-25741 (2000).
36. Kamura, T. et al. Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl Acad. Sci. USA 97, 10430-10435 (2000).
37. Bruick, R. K. & McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340 (2001).
38. 2 sensing. Science 292, 464-468 (2001).
39. 2-regulated prolyl hydroxylation. Science 292, 468-472 (2001).
40. Epstein, A. C. et al. C. elegans EGL-9 and mammalian homologs define a family of doxygenases that regulate HIF by prolyl hydroxylatlon. Cell 107, 43-54 (2001).
41. Ems, M. et al. Molecular mechanisms of transcription activation by HLF and HIF1α in response to hypoxial their stabilization and redox signal-induced interaction with CBP/p300. EMBO J. 18, 1905-1914 (1999).
42. Gu, J., Milligan, J. & Huang, L. E. Molecular mechanism of hypoxia-inducible factor 1α-p300 interaction. A leucine-rich interface regulated by a single cysteine. J. Biol. Chem. 276, 3550-3554 (2001).
43. Kung, A. L., Wang, S., Klco, J. M., Kaelin, W. G. & Livingston, D. M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nature Med. 6, 1335-1340 (2000).
44. Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J. & Whitelaw, M. L. Asparagine hydroxylation of the HIF transactivatlon domain a hypoxic switch. Science 295, 858-861 (2002).
45. McNeill, L. A. et al. Hypoxia-inducidle factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the β-carbon of asparagine-803. Biochem J. 367, 571-575 (2002).
46. Lando, D. et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16, 1466-1471 (2002).
47. Hewitson, K. S. et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family J. Biol. Chem. 277, 26351-26355 (2002).
48. Mahon, P. C., Hirota, K. & Semenza, G. L. FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15, 2675-2686 (2001).
49. Huang, L. E., Arany, Z., Livingston, D. M. & Bunn, H. F. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit. J. Biol. Chem. 271, 32253-32259 (1996).
50. Carrero, P. et al. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1α. Mol. Cell. Biol. 20, 402-415 (2000).
51. Lando, D., Pongratz, I., Poellinger, L. & Whitelaw, M. L. A redox mechanism controls differential DNA binding activities of hypoxia-inducible factor (HIF) 1α and the HIF-like factor. J. Biol. Chem. 275, 4618-4627 (2000).
52. Jeong, J. W. et al. Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell 111, 709-720 (2002).
53. Makino, Y. et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414, 550-554 (2001).
54. Makino, Y., Kanopka, A., Wilson, W. J., Tanaka, H. & Poellinger, L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor 3α locus. J. Biol. Chem. 277, 32405-32408 (2002).
55. Chun, Y. S. et al. A new HIF-1α variant induced by zinc ion suppresses HIF-1-mediated hypoxic responses. J. Cell Sci. 114, 4051-4061 (2001).
56. Chun, Y. S., Choi, E., Kim, T. Y., Kim, M. S. & Park, J. W. A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor 1α gene. Biochem J. 362, 71-79 (2002).
57. Tanguay, R. L., Andreasen, E., Heideman, W. & Peterson, R. E. Identification and expression of alternatively spliced aryl hydrocarbon nuclear translocator 2 (ARNT2) cDNAs from zebrafish with distinct functions. Biochim. Biophys. Acta 1494, 117-128 (2000).
58. Semenza, G. L. Involvement of hypoxia-inducible factor 1 in human cancer Intern. Med. 41, 79-83 (2002).
59. Karni, R., Dor, Y., Koshet, E., Meyuhas, O. & Levitzki A. Activated pp60c-Src leads to elevated HIF-1α expression under normoxia. J. Biol. Chem. 277, 42919-42925 (2002).
60. Lu, H., Forbes, R. A. & Verma, A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J. Biol. Chem. 277, 23111-23115 (2002).
61. Semenza, G. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol. 64, 993 (2002).
62. Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C. & Semenza, G. L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21, 3995-4004 (2001).
63. Harris, A. L. Hypoxia - a key regulatory factor in tumour growth, Nature Rev. Cancer 2, 38-47 (2002).
64. Ryan, H. E., Lo, J. & Johnson, R. S. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J. 17, 3005-3015 (1998).
65. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev. 12, 149-162 (1998).
66. Carmeliet, P. et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485-490 (1998).
67. Maltepe, E., Schmidt, J. V., Baunoch, D., Bradfield, C. A. & Simon, M. C. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386, 403-407 (1997).
68. Sun, X. et al. Gene transfer of antisense hypoxia inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther. 8, 638-645 (2001).
69. Isaacs, J. S. et al. Hsp9O regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J. Biol. Chem. 277, 29936-29944 (2002).
70. Mabjeesh, N. J. et al. Geldanamycin induces degradation of hypoxia-induclible factor 1 α protein via the proteosome pathway in prostate cancer cells. Cancer Res. 62, 2478-2482 (2002).
71. Blancher, C., Moore, J. W., Robertson, N. & Harris, A. L. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1α, HIF-2α, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. Cancer Pes. 61, 7349-7355 (2001).
72. Mazure, N. M., Chen, E. Y., Yeh, P., Laderoute, K. R. & Giaccia, A. J. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial grown factor expression. Cancer Res. 56, 3436-3440 (1996).
73. Kurebayashi, J. et al. A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1α and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts. Jpn J. Cancer Res. 92, 1342-1351 (2001).
74. Neckers, L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 8, S55-S61 (2002).
75. Welsh, S. et al. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1α and vascular endothelial growth factor formation. Mol. Cancer Ther. 2, 235-243 (2003).
76. Jung, F. et al. Hypoxic induction of the hypoxia-inducible factor is mediated via the adaptor protein Shc in endothelial cells. Circ. Res. 91, 38-45 (2002).
77. Chan, D. A., Sutphin, P. D., Denko, N. C. & Giaccia, A. J. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor 1α. J. Biol. Chem. 277, 40112-40117 (2002 ).
78. Jiang, B. H., Agani, F., Passaniti, A. & Semenza, G. L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 57, 5328-5335 (1997).
79. Cohen-Jonathan, E. et al. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res. 61, 2289-2293 (2001).
80. Maxwell, P. H., Pugh, O. W. & Ratcliffe, P. J. The pVHL-HIF-1 system. A key mediator of oxygen homeostasis. Adv. Exp. Med. Biol. 502, 365-376 (2001).
81. Arbiser, J. L. et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl Acad. Sci. USA 94, 861-866 (1997).
82. Jiang, B. H. et al. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 12, 363-369 (2001).
83. Mazure, N. M., Chen, E. Y., Laderoute, K. R. & Giaccia, A. J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible tactor-1 transcriptional element. Blood 90, 3322-3331 (1997).
84. Zundel, W. et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14, 391-396 (2000).
85. Cantley, L. C. & Neel, B. G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl Acad Sci. USA 96, 4240-4245 (1999).
86. Alvarez-Tejado, M. et al. Lack of evidence for the involvement of the phosphoinositide 3-kinase/Akt pathway in the activation of hypoxia-inducible factors by low oxygen tension. J. Biol. Chem. 277, 13508-13517 (2002).
87. An, W. G. et al. Stabilization of wild-type p53 by hypoxia-inducible factor 1 α. Nature 392, 405-408 (1998).
88. Blagosklonny, M. V. et al. p53 inhibits hypoxia-inducible factor stimulated transcription. J. Biol. Chem. 273, 11995-11998 (1998).
89. Thomas, G. & Hall, M. N. TOR signalling and control of cell growth. Curr. Opin. Cell Biol. 9, 782-787 (1997).
90. Hudson, C. C. et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22, 7004-7014 (2002).
91. Berra, E., Pages, G. & Pouyssegur, J. MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev. 19, 139-145 (2000).
92. Sodhi, A., Montaner, S., Miyazaki, H. & Gutkind, J. S. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1α in rasV12 upregulation of VEGF. Biochem. Biophys. Res. Commun. 287, 292-300 (2001).
93. Feldser, D. et al. Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2. Cancer Res. 59, 3915-3918 (1999).
94. Zelzer E. et al. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1α/ARNT. EMBO J. 17, 5085-5094 (1998).
95. Treins, C., Giorgetti-Peraldi, S., Murdaca, J., Semenza, G. L. & Van Obberghen, E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J. Biol. Chem. 277, 27975-27981 (2002).
96. Zhong, H. et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60, 1541-1545 (2000).
97. Neshat, M. S. et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl Acad. Sci. USA 98, 10314-10319 (2001).
98. Guba, M. et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature Med. 8, 128-135 (2002).
99. Rapisarda, A. et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62, 4316-4324 (2002).
100. Plowman, J. et al. Efficacy of the quinocarmycins KW2152 and DX-52-1 against human melanoma lines growing in culture kand in mice. Cancer Res. 55, 862-867 (1995).
101. Bunnell, C. A. et al. Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies. Cancer Chemother. Pharmacol. 48, 347-355 (2001).
102. Pribluda, V. S. et al. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev. 19, 173-179 (2000).
103. Mabjeesh, N. J. et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3, 363-375 (2003).
104. Jung, Y. J., Isaacs, J. S., Lee, S., Trepel, J. & Neckers, L. Microtubule disruption utilizes an NFκB-dependent pathway to stabilize HIF-1α protein. J. Biol. Chem. 278, 7445-7452 (2003).
105. Ko, F. N., Wu, C. C., Kuo, S. C., Lee, F. Y. & Teng, C. M. YC-1, a novel activator of platelet guanylate cyclase. Blood 84, 4226-4233 (1994).
106. Yeo, E. J. et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl Cancer Inst. 95, 516-525 (2003).
107. Li, M. et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416, 648-653 (2002).
108. Folkman, J. & Cotran, R. Relation of vascular proliferation to tumor growth. Int. Rev. Exp. Pathol. 16, 207-248 (1976).
109. Brown, J. M. & Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58, 1408-1416 (1998).
110. Cramer, T. et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 112, 645-657 (2003).
111. Vincent, K. A., Feron, O. & Kelly, R. A. Harnessing the response to tissue hypoxia: HIF-1α and therapeutic angiogenesis. Trends Cardiovasc. Med. 12, 362-367 (2002).
112. Vincent, K. A. et al. Angiogenesis is induced in a rabbit model of hindlimin schemia by naked DNA encoding an HIF-1α/VP16 hybrid transcription factor. Circulation 102, 2255-2261 (2000).
113. Belanger, A. J. et al. Hypoxia up-regulates expression of peroxisome proliferator-activated receptor-γ angiopoietin-related gene (PGAR) in cardiomyocytes: role of hypoxia inducible factor 1α. J. Mol. Cell. Cardiol. 34, 765-774 (2002).
114. Jiang, C. et al. Gene expression profiles in human cardiac cells subjected to hypoxia or expressing a hybrid form of HIF-1α. Physiol. Genomics 8, 23-32 (2002).
115. Nwogu, J. I. et al. Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation 104, 2216-2221 (2001).
116. Park, S. et al. Hypoxia-induced gene expression occurs solely through the action of HIF-1α: The role of cytoplasmic trapping of HIF-2α. Mol. Cell. Biol. 23, 4959-4971 (2003).